Observed Signal · Sep 29, 2026 · Partnership · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive
Apheris and Ginkgo Launch Antibody Developability Consortium
Berlin-based Apheris and Ginkgo Bioworks' Ginkgo Datapoints have launched the Antibody Developability Consortium, an industry collaboration to build the largest standardized antibody developability dataset. Founding members include AbbVie, argenx, Lundbeck, and Takeda, who will contribute proprietary antibody sequences. The consortium aims to train AI models on 10,000 antibodies using Apheris's federated data infrastructure, which allows members to train and refine models without exposing proprietary data. Ginkgo Datapoints will lead scientific design and execution, while Apheris provides the secure environment for model training. The initial dataset is expected by early 2027. This initiative addresses the lack of large, standardized datasets for predicting antibody manufacturability and developability, potentially reducing development time and costs for pharmaceutical companies.
This collaboration between pharma giants and AI-driven data platforms showcases the growing importance of federated learning and privacy-preserving AI in drug development, potentially accelerating innovation in biotech and influencing AdTech applications of federated data.
Track AbbVie Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Apheris and Ginkgo Datapoints announced the launch of the Antibody Developability Consortium.
- Founding members include AbbVie, argenx, Lundbeck, and Takeda.
- The consortium aims to train AI on 10,000 antibodies.
- Ginkgo Datapoints leads scientific design and execution.
- Initial dataset expected by early 2027.
Connected Companies & Entities
1 Entity mapped“The founding members of the consortium include AbbVie (United States)....”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Vivodyne builds robotic labs to improve AI drug discovery
Vivodyne, a biotech startup spun out of the University of Pennsylvania, says the AI drug‑discovery field lacks the causal human biological data needed to train useful models and has built HIVE — modular robotic labs that grow human tissues, autonomously dose and monitor them, and generate longitudinal experimental data. The company claims its tissues achieve high concordance with human trial outcomes (e.g., liver 94%, airway 96%, bone marrow 100% on tested chemotherapies), has raised just under $80 million across two rounds led by Khosla Ventures, and last week opened what it calls the world’s largest “human data center” near San Francisco to scale throughput and feed AI research. Vivodyne positions its dataset as a way to enable causal, reinforcement‑learning style models for more predictive human biology and combination‑therapy design.
DataLab Launches to Bridge AI's Critical Data Gap
Bobby Samuels, CEO of Protege, announces DataLab, a dedicated research institution within Protege focused on closing the "data gap" that Samuels identifies as a core bottleneck for frontier AI progress. DataLab aims to combine large-scale data access with rigorous dataset research, curation, and experimentation—building multimodal healthcare benchmarks, frameworks for agentic task selection, dataset-quality scoring methods (described as "FICO scores" for AI data), and research on contamination, factuality, de‑identification, representational bias, and measurement. Samuels argues that while model and compute labs are well-established, the data layer lacks a comparable institution and that solving data-level challenges is essential to unlock the next generation of AI capabilities.
Anthropic launches AI drug discovery program
Anthropic announced an internal AI-driven drug discovery program focused on treatments for neglected diseases and unveiled Claude Science, an AI workbench aimed at life sciences companies. At a San Francisco event, Anthropic executives said running their own discovery efforts will help build better models and tools to sell to drugmakers. The company did not detail next steps for any drug candidates. The article situates Anthropic’s move within a broader trend of major tech companies (Alphabet, Apple, Amazon) increasing activity in healthcare, and notes Amazon’s acquisitions of One Medical and PillPack now sit in a division called Amazon Health Services.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.